KLRK1 and neoplasm: NK cells form a first line of defense against tumor cells [6] and the responsiveness is modulated by engagement of activating receptors, such as NKG2D, on the NK cells with the activating ligands, such as NKG2D ligands (NKG2DL) on the tumor cells [7, 8].